Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
10.24 USD -1.06% Intraday chart for Embecta Corp. -10.18% -45.91%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Embecta Keeps Quarterly Dividend at $0.15 a Share, Payable March 15 to Shareholders as of Feb. 28 MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday MT
Sector Update: Health Care MT
Transcript : Embecta Corp., Q1 2024 Earnings Call, Feb 09, 2024
Embecta's Fiscal Q1 Adjusted Earnings Decline, Revenue Rises; Fiscal 2024 Guidance Lifted MT
Embecta Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Embecta Corp. Updates Earnings Guidance for the Fiscal Year 2024 CI
(EMBC) EMBECTA Forecasts Fiscal Year 2024 EPS Range $1.95 - $2.15 MT
Earnings Flash (EMBC) EMBECTA Posts Q1 Revenue $277.3M MT
Earnings Flash (EMBC) EMBECTA Posts Q1 EPS $0.61 MT
North American Morning Briefing : Stock Futures Rise; S&P 500 Again Tests 5,000 Milestone DJ
Embecta Corp. Declares Quarterly Cash Dividend, Payable on March 15, 2024 CI
Embecta Corp. Seeks M&A CI
Transcript : Embecta Corp. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 02:15 PM
Embecta Submits Premarket Filing to FDA for Insulin Patch Pump MT
Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch Pump CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Embecta Says Its Syringes Are Not Affected by US FDA Safety Warning MT
Morgan Stanley Adjusts Price Target on to $16 From $15, Maintains Underweight Rating MT
Transcript : Embecta Corp., Q4 2023 Earnings Call, Nov 21, 2023
North American Morning Briefing : All Eyes on -2- DJ
Embecta Keeps Quarterly Dividend of $0.15 a Share, Payable Dec. 15 to Shareholders as of Dec. 4 MT
(EMBC) EMBECTA Expects Fiscal Year 2024 EPS Range $1.90 - $2.10 MT
Earnings Flash (EMBC) EMBECTA Posts Q4 Revenue $281.9M MT
Chart Embecta Corp.
More charts
Embecta Corp. is a global medical device company. The Company is focused on providing solutions to people living with diabetes. The Company has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The Company also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through a variety of channels, including retail, hospitals, pharmacies and other institutional channels.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
10.24 USD
Average target price
16.5 USD
Spread / Average Target
+61.13%
Consensus
  1. Stock Market
  2. Equities
  3. EMBC Stock
  4. News Embecta Corp.
  5. BofA Securities Initiates Embecta at Underperform with $25 Price Target